Rarestone

RareStone Group (琅钰集团) is a China-based biotech holding company committed to establishing Greater China's first integrated rare disease ecosystem, transforming the lives of patients and their families. Formerly known as Citrine Medicine, the company consists of two core business subsidiaries focused on late clinical-stage rare disease medicine development and commercialization in China. RareStone pursues drug approvals through innovative approaches including real-world evidence (RWE) data strategies, and has announced strategic collaborations with partners such as Tencent Holdings to build a service ecosystem centered on rare disease patients in China. The company operates at the intersection of clinical drug development, patient advocacy, and digital health services to address the significant unmet needs of the rare disease patient population across Greater China, where regulatory pathways and reimbursement infrastructure for rare diseases have historically been underdeveloped.